More Human BM-MSC With Similar Subpopulation Composition and Functional Characteristics Can Be Produced With a GMP-Compatible Fabric Filter System Compared to Density Gradient Technique
暂无分享,去创建一个
[1] A. Kretschmer,et al. Modulating endothelial adhesion and migration impacts stem cell therapies efficacy , 2020, EBioMedicine.
[2] A. Kretschmer,et al. Cell motility and migration as determinants of stem cell efficacy , 2020, EBioMedicine.
[3] D. Stroncek,et al. Human Mesenchymal Stromal Cell (MSC) Characteristics Vary Among Laboratories When Manufactured From the Same Source Material: A Report by the Cellular Therapy Team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative , 2020, Frontiers in Cell and Developmental Biology.
[4] M. Grumet,et al. Trends in mesenchymal stem cell clinical trials 2004‐2018: Is efficacy optimal in a narrow dose range? , 2019, Stem cells translational medicine.
[5] K. Bieback,et al. Gaps in the knowledge of human platelet lysate as a cell culture supplement for cell therapy: A joint publication from the AABB and the International Society of Cell Therapy. , 2019, Cytotherapy.
[6] K. Bieback,et al. Production and quality testing of multipotent mesenchymal stromal cell therapeutics for clinical use , 2019, Transfusion.
[7] Peter Bader,et al. Molecular signature of human bone marrow-derived mesenchymal stromal cell subsets , 2019, Scientific Reports.
[8] Matthias M. Aitzetmüller,et al. Single‐Cell Transcriptomics of Human Mesenchymal Stem Cells Reveal Age‐Related Cellular Subpopulation Depletion and Impaired Regenerative Function , 2018, Stem cells.
[9] D. Strunk,et al. Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] D. Bueno,et al. The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review , 2018, Front. Immunol..
[11] M. Longaker,et al. Mesenchymal Stromal Cells and Cutaneous Wound Healing: A Comprehensive Review of the Background, Role, and Therapeutic Potential , 2018, Stem cells international.
[12] K. Swiech,et al. Mesenchymal Stromal Cells: From Discovery to Manufacturing and Commercialization , 2018, Stem cells international.
[13] G. Lucchini,et al. Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM) , 2018, Bone Marrow Transplantation.
[14] M. Pittenger,et al. Corrigendum to: Concise Review: MSC‐Derived Exosomes for Cell‐Free Therapy , 2017, Stem cells.
[15] K. Tarte,et al. Brief Report: Proteasomal Indoleamine 2,3‐Dioxygenase Degradation Reduces the Immunosuppressive Potential of Clinical Grade‐Mesenchymal Stromal Cells Undergoing Replicative Senescence , 2017, Stem cells.
[16] F. Rodeghiero,et al. Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future , 2016, Stem Cell Research & Therapy.
[17] R. Schäfer,et al. Mesenchymal Stem/Stromal Cells in Regenerative Medicine: Can Preconditioning Strategies Improve Therapeutic Efficacy , 2016, Transfusion Medicine and Hemotherapy.
[18] T. Bliss,et al. High-Resolution Microfluidic Single-Cell Transcriptional Profiling Reveals Clinically Relevant Subtypes among Human Stem Cell Populations Commonly Utilized in Cell-Based Therapies , 2016, Front. Neurol..
[19] Huey-Kang Sytwu,et al. CD146+ mesenchymal stem cells display greater therapeutic potential than CD146– cells for treating collagen-induced arthritis in mice , 2016, Stem Cell Research & Therapy.
[20] T. Klingebiel,et al. In vitro migration and proliferation (“wound healing”) potential of mesenchymal stromal cells generated from human CD271+ bone marrow mononuclear cells , 2015, Journal of Translational Medicine.
[21] E. Jones,et al. Where is the common ground between bone marrow mesenchymal stem/stromal cells from different donors and species? , 2015, Stem Cell Research & Therapy.
[22] Alan Trounson,et al. Stem Cell Therapies in Clinical Trials: Progress and Challenges. , 2015, Cell stem cell.
[23] H. Northoff,et al. Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells , 2013, BMC Medicine.
[24] H. Northoff,et al. Mesenchymal stromal/stem cells markers in the human bone marrow. , 2013, Cytotherapy.
[25] T. Olson,et al. Improved isolation and expansion of bone marrow mesenchymal stromal cells using a novel marrow filter device. , 2013, Cytotherapy.
[26] P. Giannoudis,et al. Transcriptional profile of native CD271+ multipotential stromal cells: evidence for multiple fates, with prominent osteogenic and Wnt pathway signaling activity. , 2012, Arthritis and rheumatism.
[27] T. Redmer,et al. Replicative aging and differentiation potential of human adipose tissue-derived mesenchymal stromal cells expanded in pooled human or fetal bovine serum. , 2012, Cytotherapy.
[28] P. Giannoudis,et al. Single-platform quality control assay to quantify multipotential stromal cells in bone marrow aspirates prior to bulk manufacture or direct therapeutic use. , 2012, Cytotherapy.
[29] F. Fagioli,et al. Multipotent Mesenchymal Stromal Stem Cell Expansion by Plating Whole Bone Marrow at a Low Cellular Density: A More Advantageous Method for Clinical Use , 2011, Stem cells international.
[30] R. Henschler,et al. CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties , 2010, Haematologica.
[31] S. Kimura,et al. A novel method to isolate mesenchymal stem cells from bone marrow in a closed system using a device made by nonwoven fabric. , 2010, Tissue engineering. Part C, Methods.
[32] F Beaujean,et al. Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. , 2005, The Journal of bone and joint surgery. American volume.
[33] M. Pittenger,et al. Unraveling the Mesenchymal Stromal Cells' Paracrine Immunomodulatory Effects. , 2016, Transfusion medicine reviews.
[34] J. Galipeau. The mesenchymal stromal cells dilemma--does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? , 2013, Cytotherapy.
[35] A. Ho,et al. Isolation of human mesenchymal stromal cells is more efficient by red blood cell lysis. , 2008, Cytotherapy.
[36] D. Prockop,et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.
[37] ANTHONY WREN,et al. Population Growth , 1972, Nature.